AstraZeneca Pharma India Ltd. — Earnings Release 2025

May 30, 2025

==> picture [503 x 53] intentionally omitted <==

May 30, 2025

The Manager – Listing BSE Limited 1[st] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the audited financial results for the financial year ended March 31, 2025.

Thanking you,

For AstraZeneca Pharma India Limited

Digitally signed MANAS by MANASA RAMA A RAMA Date: 2025.05.30 19:22:10 +05'30'

Manasa. R Company Secretary

==> picture [452 x 64] intentionally omitted <==

News Release

==> picture [111 x 36] intentionally omitted <==

AstraZeneca Pharma India Limited marks a consistent 32 % growth as the company announces its annual results for FY 2024-25

Total Revenue from opera�ons is INR 17162.9 Mn - up by 32% and Core EPS announced as INR 46.30

Bengaluru, May 30, 2025: AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceu�cal company, today announced its full year performance for the financial year April 2024March 2025. The Company sustained its momentum from previous quarters and recorded a significant year-on-year growth across therapeu�c areas, achieving a 32% increase in revenue compared to the same period last year.

Financial performance Summary -

==> picture [484 x 190] intentionally omitted <==

----- Start of picture text -----

Summary Q4 Jan’24- Full year Q4 Full year
Mar’24 Apr’23-Mar’24 Jan'25 – Mar'25 Apr’24-
(Value in INR (Value in Mar’25
Mn) INR Mn)
Total Revenue from Opera�on 3832.0 12955.3 4804.8 17162.9
Profit before excep�onal item and 543.6 2031.1 841.5 2531.5
tax
Profit a�er excep�onal item and tax 394.8 1615.1 582.5 1157.4
TA wise Oncology 2399.6 7510.9 3158.5 11171.4
performance Biopharmaceu�cals 1204.6 4537.0 1227.4 4881.2
(CVRM, R&I and V&I)
Rare Disease 1.7 8.5 20.0 31.7
----- End of picture text -----

, said, "FY 2024-25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32%. This reflects our strategic focus on science, specialist, and the strength of our innova�on-led por�olio. As we scale impact across therapy areas, we remain commi�ed to delivering sustainable value to the people, society and the planet."

Dr. Sanjeev Panchal, Country President & Managing Director of the Company, said , "Our company delivered a strong growth in Financial Year 2024-25 by bringing innova�ve medicine launches in India, giving us a momentum into 2025 and beyond. We are pleased to share that our company has for the first �me crossed the INR 1700 cr mark ($200 Mn). Science is sustaining and growing the success of our company, helping us transform the future of healthcare, and the health of people, society and the planet.”

News Release

==> picture [111 x 36] intentionally omitted <==

Key milestones:

• Since 2023, the Company has delivered 14 approvals across its por�olio- Oncology, Biopharmaceu�cal, Rare Disease.

• In FY ’24- ‘25 the company announced regulatory approvals for:

• Palivizumab (50mg/0.5mL): Following the receipt of approval from Drugs Controller General of India (DCGI) in September 2023, the Company launched Palivizumab (50mg/0.5ml) in October 2024. This monoclonal an�body is indicated for the preven�on of serious lower respiratory tract disease caused by respiratory syncy�al virus (RSV) in high-risk paediatric pa�ents.

• Tremelimumab (25mg/mL) : Following DCGI approval in May 2023, the company launched Tremelimumab in October 2024. Tremelimumab in combina�on with Durvalumab (Imfinzi) is indicated for the treatment of pa�ents with unresectable hepatocellular carcinoma (uHCC).

• Durvalumab – Addi�onal Indica�on (NSCLC) : Secured Central Drugs Standard Control Organiza�on’s (CDSCO) approval in September 2024 for an addi�onal indica�on—neoadjuvant and adjuvant use in resectable NSCLC (tumors ≥4 cm and/or node-posi�ve), in combina�on with chemotherapy and as monotherapy post-surgery.

• Olaparib + Durvalumab (Endometrial Cancer) : Received CDSCO approval for the addi�onal indica�on for the maintenance treatment of adult pa�ents with advanced or recurrent endometrial cancer who have not progressed following first-line treatment with Durvalumab in combina�on with pla�num-based chemotherapy.

• Budesonide/Glycopyrronium/Formoterol: Approved by CDSCO in December 2023 and launched in January 2025, this is indicated for maintenance treatment in adults with chronic obstruc�ve pulmonary disease (COPD) to relieve symptoms and prevent exacerba�ons.

• Eculizumab (300mg/30mL) : Approved for import and distribu�on by CDSCO, this is indicated for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemoly�c Uremic Syndrome (aHUS) to inhibit complement – mediated thrombo�c microangiopathy.

• Durvalumab – Addi�onal Indica�on : Gained CDSCO approval in March 2025 for use of Durvalumab in combina�on with Tremelimumab for the treatment of pa�ents with unresectable hepatocellular carcinoma (uHCC)

• Sodium Zirconium Cyclosilicate (5g/10g): Received CDSCO permission for import and sale in March 2025. This novel oral suspension significantly improves hyperkalaemia management in adults, commonly associated with cardiovascular, renal, and metabolic condi�ons.

• Durvalumab: Addi�onal Indica�on : Gained CDSCO approval in March 2025 for use of Durvalumab for the treatment of pa�ents with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following pla�num-based chemoradia�on therapy (CRT).

• Partnership for Health System Sustainability and Resilience (PHSSR) commissioned independent report was presented at the Embassy of Sweden in the presence of key dignitaries from the Ministry of Health & Family Welfare, key influencers from the healthcare ecosystem followed by a deep delibera�on on how private and public sectors need to jointly priori�se areas of concern that emerged from the COVID-19 pandemic and prepare the Indian health system to tackle crises when needed.

Key Appointments

• Ms. Monica Widhani was appointed as an Independent Director on the Board of the Company, with effect from September 25, 2024

• Ms. Shilpa Divekar Nirula , Independent Director has been unanimously elected as Chairperson of the Board, effec�ve September 30, 2024

• Mr. Jesus Javier Diaz Ropero Esteso was appointed as a Non-Execu�ve Director of the Company with effect from November 13, 2024

• Ms. Shikha Mirchandani Chatrath was appointed as Director – Commercial Excellence, BD & Strategy with effect from June 17, 2024

News Release

==> picture [111 x 36] intentionally omitted <==

• Ms Amita Bhave November 18, 2024

• Dr. Sandeep Arora

• Harish Dash 2025.

Recogni�ons:

• The Company was recognised for a valuable contribu�on in spreading large scale awareness on RSV in the country at Na�onal Neonatology Forum Program - NEOCON 2024

• The Company was awarded a ‘Great Place To Work’ for the seventh consecu�ve �me

• The Company was awarded ‘ET Now Progressive Company of the year’ for demonstra�ng an excep�onal commitment to workplace excellence and contribu�ng significantly to industry success.

• Recognized as one of ‘India's Best Organiza�ons in Innova�on’ by ET Now

• Awarded ‘Pharma InHouse Legal Team of the Year’ at the 13th Annual Legal Era - Indian Legal Awards 2023-24

• Amarpreet Kaur Ahuja, Country HR Director, was featured among “The Powerhouses of Indian HR: Women Driving Change and Innova�on” by Indian Conven�ons

• Diversity and Inclusion Award 2024 at the 57th OPPI Annual Day

• Awarded ‘Silver’ for Best Employer for Women in Small Category at the ASSOCHAM 5th Diversity & Inclusion Excellence Awards & Conclave – 2024

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceu�cal company that focuses on the discovery, development and commercialisa�on of prescrip�on medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innova�ve medicines are used by millions of pa�ents worldwide. Comple�ng its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country commi�ed to deliver great medicines to pa�ents through innova�ve science and global excellence in development and commercializa�on. For more informa�on, please visit our website: h�ps://www.astrazeneca.in/ or follow us on LinkedIn: AstraZeneca India.